Implication of genetic variants near SLC30A8, HHEX, CDKAL1, CDKN2A/B, IGF2BP2, FTO, TCF2, KCNQ1, and WFS1 in Type 2 Diabetes in a Chinese population

Xueyao Han†, Yingying Luo, Qian Ren, Xiuying Zhang, Fang Wang, Xiuqin Sun, Xianghai Zhou and Linong Ji*

Abstract

**Background:** Recently, several genome-wide and candidate gene association studies have identified many novel genetic loci for type 2 diabetes (T2D); among these genes, CDKAL1, IGF2BP2, SLC30A8, CDKN2A/B, HHEX, FTO, TCF2, KCNQ1, and WFS1 are the most important. We aimed to determine the effects of these genetic loci associated with T2D in the Chinese Han population of China.

**Methods:** Single-nucleotide polymorphisms (SNPs) in or near CDKAL1, IGF2BP2, SLC30A8, CDKN2A/B, HHEX, FTO, TCF2, KCNQ1, and WFS1 genes were genotyped in a case-control Chinese Han sample living in Beijing, China involving 1024 patients with T2D and 1005 control subjects.

**Results:** In Chinese Han, we replicated the associations between 7 genetic loci and T2D, with risk allele-specific odds ratios (ORs) as follows: 1.27 (95% CI, 1.11-1.45; p = 0.0008) for CDKAL1-rs10946398, 1.26 (95% CI, 1.08-1.47; p = 0.003) for IGF2BP2-rs4402960, 1.19 (95% CI, 1.04-1.37; p = 0.009) for SLC30A8-rs1326634, 1.22 (95% CI, 1.06-1.41; p = 0.005) for CDKN2A/B-rs10811661, 1.20 (95% CI, 1.01-1.42; p = 0.03) for HHEX-rs5015480, 1.37 (95% CI, 1.19-1.69; p = 1.0 × 10^-4) for KCNQ1-rs2237892, and 1.24 (95% CI, 1.01-1.52; p = 0.046) for FTO-rs8050136 after adjustment for age, gender, and body mass index. Not only did an association between WFS1-rs6446482 and early-onset T2D exist in the subgroup analysis, but TCF2-rs7501939 and WFS1-rs6446482 were also confirmed to confer risk for T2D in this meta-analysis. Moreover, the relationship between FTO-rs8050136 and body mass index, together with the effect of CDKAL1-rs10946398 on beta cell function, was also observed in the control individuals.

**Conclusions:** Our findings support the important contribution of these genetic loci to susceptibility for T2D in the Chinese Han population in Beijing of China.

Background

Genome-wide association studies (GWAS) have identified many novel susceptibility genes for type 2 diabetes (T2D) since 2007. In the early GWAS, common variants in IGF2BP2, CDKAL1, SLC30A8, HHEX, CDKN2A/B, FTO, and TCF2 loci were reported to increase the risk of T2D in Caucasians [1-6], and KCNQ1 was recently discovered as a new diabetogenic gene in Japanese samples [7]. In addition, the Wolfram syndrome 1(WFS1) gene is one of the novel susceptibility genes for T2D identified by the candidate gene approach in Caucasians until recently [8]. Compared with the susceptibility genes for T2D revealed in the following meta-analysis of GWAS [9], these 9 genes, which were discovered in relatively smaller samples, might represent the most diabetogenic genes and have larger effect sizes in the studied populations. Although these associations have been replicated in Caucasians, the roles of some loci remain less clear in Chinese. For example, in the Chinese Han population, the associations between single nucleotide polymorphisms (SNPs) at the HHEX, IGF2BP2, TCF2, and FTO loci with T2D were not consistently replicated [6,10-15], and the findings in previous studies involving Caucasians for SNPs at the WFS1 locus have not been confirmed [12]. Moreover, in contrast to the large-scale association stud-
ies in a European Caucasian population, such studies in China often have a relatively small sample size, and meta-analysis is becoming particularly useful to evaluate the effects of these genes.

Therefore, we hypothesized that the aforementioned genes were also the most important susceptibility genes for T2D in the Chinese Han population living in China. We aimed to test this hypothesis in a case-control study and perform a meta-analysis of all published data for these genetic loci in the Chinese Han population to fully evaluate their effects.

**Methods**

**Subjects**

A total of 2029 individuals, including 1024 patients with T2D and 1005 control subjects, were included in the present study. All participants were unrelated and of Northern Han Chinese ancestry residing in the Beijing metropolitan area. The patients were recruited from the Endocrinology and Metabolism Outpatient Clinics of Peking University People's Hospital in Beijing, China, and were diagnosed with T2D in accordance with the 1999 WHO criteria (fasting plasma glucose ≥7.0 mmol/l and/or 2-h plasma glucose ≥11.1 mmol/l) [16]. Patients diagnosed with T2D before 30 years of age, those with an elevated body mass index (BMI: > 35 kg/m²), or those with other clinical and genetic features for specific-type diabetes (e.g., maturity onset diabetes of the young [MODY]) were excluded from the study [17,18]. The control subjects were selected from communities near Peking University People's Hospital. The inclusion criteria for the control subjects in this study were as follows: (1) normal glucose regulation confirmed by a 75 g oral glucose tolerance test (OGTT) according to the 1999 WHO criteria (fasting plasma glucose <6.1 mmol/l and 2-h plasma glucose <7.8 mmol/l), (2) no family history of T2D, (3) >40 years of age, and (4) a BMI ≤ 35 kg/m². The clinical features of the participants are summarized in Table 1. Informed consent was obtained from every participant, and the study protocol was approved by the Ethics Committee of Peking University People's Hospital.

**Anthropometric and biological measurements**

All of the patients with T2D and control subjects were examined in the morning after an overnight fast for at least 8 hours, with measurements of height, weight, and blood pressure. Blood samples were collected for biochemical measurements of fasting plasma glucose for all the participants, and 2-hour plasma glucose during a 75 g OGTT for the controls. The plasma glucose concentrations were measured by the glucose oxidase-peroxidase method. The fasting serum insulin concentrations were measured by an electrochemiluminescence immunoassay on a Roche Elecsys 2010 Chemistry Analyzer. The homeostasis model assessment of the insulin resistance index (HOMA-IR) and beta-cell function (HOMA-β) were assessed, as described previously [19].

**Genotyping**

Nine SNPs representing nine genes identified in recent GWAS or large candidate gene studies [1-8] were selected, including SLC30A8-rs13266634, HHEX-rs5015480, CDKAL1-rs10946398, CDKN2A/B-rs10811661, IGFBP2-rs4402960, FTO-rs8050136, TCF2-rs7501939, KCNQ1-rs2237892, and WFS1-rs6446482. Genotyping of these SNPs was performed with an ABI SNaPshot Multiplex System (Applied Biosystems, Foster City, CA, USA) in the Chinese National Human Genome Center in Shanghai. Genotyping accuracy, as determined from the genotype concordance between duplicate samples (130 samples), was 100%. The genotyping success rate was >95% for the patient and control groups.

**Statistical analysis**

Data are given as the means ± SD for quantitative variables with a normal distribution, and as medians (inter-quartile range) for non-normally distributed data. Fasting serum insulin, HOMA-IR, and HOMA-β were natural logarithm-transformed to normal distributions before statistical analysis.

Characteristics were compared and tested for significant differences between patients and controls using Student’s t test for continuous variables, and using χ² test for categorical variable. Chi-squared tests were used to determine whether or not individual polymorphisms were in Hardy-Weinberg equilibrium (p > 0.05). The differences in allele and genotype frequencies between the patients with T2D and controls were analyzed using Pearson’s χ² test. Logistic regression analysis was performed to calculate risk allele-specific odds ratios (ORs), 95% confidential intervals (CIs), and corresponding p-values after adjustment for gender, age, and BMI as covariates; under an additive model, 10,000 permutations were used to obtain a true estimate for statistical significance.

Linear regression was applied to test quantitative variables for differences between the genotype groups. SNPs that showed nominal evidence for an association between the age of diagnosis (AOD) for T2D, fasting plasma glucose, fasting serum insulin, HOMA-IR, and HOMA-β were adjusted by age, gender and BMI. Additionally, BMI was adjusted for age and gender. All analyses were adjusted using linear regression on a priori genotypic models (dominant, additive, and recessive). Due to a lack of validity of the large sample χ² test statistic, only the dominant model was considered for SNPs with ≤10 indi-
individuals homozygous for the minor allele (for WFS1 and FTO loci in the present study).

All statistical tests were performed by PLINK, version 1.06 [http://pngu.mgh.harvard.edu/~purcell/plink] or SPSS, version 11.5 for Windows (SPSS, Inc., Chicago, IL, USA). A p-value < 0.05 was considered statistically significant (two-tailed).

Power calculations were performed using Quanto software (available at [http://hydra.usc.edu/gxe]), and the powers shown in Additional file 1, Table S1 were calculated using ORs from published studies, sample sizes and minor allele frequencies (MAF) in the present study, the prevalence of T2D in Chinese of mainland China [20], and the type 1 error rate (0.05).

Pairwise linkage disequilibrium (LD) coefficients ($r^2$) between SNPs were calculated by Haploview software, version 4.0 (Daly Lab at the Broad Institute, Cambridge, MA, USA).

To identify studies eligible for meta-analysis, MEDLINE citations (January 2000-January 2010) were surveyed using the National Library of Medicine's PubMed on-line search engine with each susceptibility gene name (CDKAL1, IGF2BP2, SLC30A8, CDKN2A/B, HHEX, KCNQ1, FTO, TCF2, and WFS1) and Chinese as key words. The retrieved references were read to identify studies that examined the allelic associations between the SNPs within the above nine genetic regions and T2D in Chinese Han living in China. For meta-analysis of WFS1, FTO, and TCF2, the C allele of WFS1-rs6446482, the A allele of FTO-rs8050136, and the T allele of TCF2-rs7501939 were used as surrogates for the minor A allele of WFS1-rs10010131, the A allele of FTO-rs99399609, and the G allele of TCF2-rs4430796 because they are in strong LD ($r^2 = 1$) in a HapMap Chinese Han population. In the meta-analysis, Cochran’s $\chi^2$-based Q-statistic test was performed to assess heterogeneity in all of the studies included, and a random-effect model was adopted when heterogeneity existed, otherwise a fixed-effects model was appropriate. Combined ORs were calculated using the Mantel-Haenszel (fixed-effects) and DerSimonian and Laird (random-effects) tests. The significant P value of overall ORs was determined using the Z-test. All calculations for the meta-analysis were performed on Revman42 (provided by Cochrane-Collaboration, available at [http://ims.cochrane.org/revman/download/revman-4]).

**Results**

**Association study**

We have successfully genotyped all nine SNPs. There were no significant departures from the Hardy-Weinberg equilibrium for all SNPs in the control group (p > 0.05) as assessed by a $\chi^2$-test. In Table 2, we present for each SNP the genotype and allele distributions, risk allele-specific ORs, and p-values under an additive genetic model after correction for gender, age, and BMI. The allele frequencies of all SNPs in our studied population (Additional file 1, Table S1) are comparable to those of the Chinese Han population and different from Europeans in HapMap ([http://www.hapmap.org/], accessed Feb 2009). The associations of 7 SNPs with T2D were observed, which included, as follows: CDKAL1-rs10946398 (OR, 1.27; 95% CI, 1.11-1.45; empirical p = 0.0008); IGF2BP2-rs4402960 (OR, 1.26; 95% CI, 1.08-1.47; empirical p = 0.003); SLC30A8-rs13266634 (OR, 1.19; 95% CI, 1.04-1.37; empirical p = 0.009); CDKN2A/B-rs10811661 (OR, 1.22; 95% CI, 1.06-1.41; empirical p = 0.005); HHEX-rs5015480 (OR,1.20; 95% CI, 1.01-1.42; empirical p = 0.03); and KCNQ1-rs12237892 (OR, 1.37; 95% CI, 1.19-1.69; empirical p = 1.0 × 10^{-9}). Interestingly, FTO-rs8050136 was also...
| Chr | SNPs     | Genes      | Genotypes distribution a | Genotypic Pnominal | Minor/Major Alleles | RAF | Odd ratio (95%CI) | Allelic Pnominal c | Allelic Ppermuted d |
|-----|----------|------------|--------------------------|-------------------|---------------------|-----|-------------------|-------------------|-------------------|
|     |          | Patients bb/Bb/BB | Controls Bb/Bb/BB | Patients Controls |
| 9   | rs10811661 | CDKN2A/B   | 145:514:343             | 191:514:279       | 0.002               | C/T | 0.60              | 0.55              | 1.22(1.06-1.41)    | 0.005              | 0.005              |
| 8   | rs1326634  | SLC30A8    | 149:457:386             | 179:487:327       | 0.01                | T/C | 0.62              | 0.57              | 1.19(1.04-1.37)    | 0.009              | 0.009              |
| 4   | rs6446482  | WFS1       | 0:71:914                | 2:91:880          | 0.06                | C/G | 0.96              | 0.95              | 1.39(0.98-1.92)    | 0.06               | 0.06               |
| 10  | rs5015480  | HHEX       | 43:336:627              | 31:290:668        | 0.04                | C/T | 0.21              | 0.18              | 1.20(1.01-1.42)    | 0.03               | 0.03               |
| 17  | rs7501939  | TCF2       | 89:443:460              | 73:378:490        | 0.04                | T/C | 0.31              | 0.28              | 1.12(0.97-1.30)    | 0.12               | 0.12               |
| 6   | rs10946398 | CDKAL1     | 240:472:286             | 170:498:323       | 0.0006              | C/A | 0.48              | 0.42              | 1.27(1.11-1.45)    | 0.0006             | 0.0008             |
| 16  | rs8050136  | FTO        | 17:229:761              | 10:195:790        | 0.08                | A/C | 0.13              | 0.11              | 1.24(1.01-1.52)    | 0.041              | 0.046              |
| 3   | rs4402960  | IGF2BP2    | 76:418:503              | 53:356:571        | 0.001               | T/G | 0.29              | 0.24              | 1.26(1.08-1.47)    | 0.003              | 0.003              |
| 11  | rs2237892  | KCNQ1      | 69:396:525              | 107:437:415       | 1.23 × 10⁻⁵         | T/C | 0.73              | 0.66              | 1.37(1.19-1.69)    | 2.47 × 10⁻⁵        | 1.0 × 10⁻⁴          |

a. Genotype distributions are shown as the counts of three genotypes (bb, Bb, and BB). b. Minor allele; B, Major allele. RAF, Risk allele; OR, Risk allele-specific odds ratios calculated by logistic regression analysis. c. Adjusted for age, gender, and BMI. d. Permutation for 10,000 times. Bold indicates the risk allele.
associated with T2D (OR, 1.25; 95% CI, 1.02-1.52; empirical p = 0.029), which remained significant after adjustment for age, gender, and BMI (OR, 1.24; 95% CI, 1.01-1.52; empirical p = 0.046). However, no association with diabetes was found for TCF2-rs7501939 and WFS1-rs6446482.

**Meta-analysis**

All published studies and references are shown in Additional file 1, Table S2, which indicates the inconsistency of associations between HHEX, IGF2BP2, TCF2, and FTO with T2D, the low MAF of WFS1-rs6446482 and FTO-rs8050136, and the small sample sizes in all studies in Chinese compared with those in Caucasian populations. Except for the Li study [13] due to the lack of allelic frequencies, the data from other studies and the current study were included in this meta-analysis to improve the power in evaluating the collective evidence on the relationships of these nine genetic loci to T2D, especially HHEX, IGF2BP2, TCF2 FTO, and WFS1 genetic loci. Table 3 shows the outcome of the meta-analysis. Overall, the pooled ORs for T2D were significant for rs8050136, and the small sample sizes in all studies in Chinese compared with those in Caucasian populations. Except for the Li study [13] due to the lack of allelic frequencies, the data from other studies and the current study were included in this meta-analysis to improve the power in evaluating the collective evidence on the relationships of these nine genetic loci to T2D, especially HHEX, IGF2BP2, TCF2 FTO, and WFS1 genetic loci. Table 3 shows the outcome of the meta-analysis. Overall, the pooled ORs for T2D were significant for HHEX-rs5015480 (pooled OR, 1.24; p < 0.00001), IGF2BP2-rs4402960 (pooled OR, 1.14; p = 0.002), TCF2-rs7501939 (pooled OR, 1.16; p < 0.00001), FTO-rs8050136 (pooled OR, 1.26; p = 0.009), CDKAL1-rs10946398 (pooled OR, 1.24; p < 0.00001), SLC30A8-rs13266634 (pooled OR, 1.19; p < 0.00001), CDKN2A/B-rs10811661 (pooled OR, 1.28; p < 0.00001), and KCNQ1-rs2237892 (pooled OR, 1.33; p < 0.00001).

Table 3: Meta-analysis for SNPs at nine genetic loci in the Chinese Han population living in China.

| Chr | SNP    | Gene       | Risk allele | Case risk AF | Control risk AF | P for heterogeneity | OR (95%CI) | P for overall effect | References |
|-----|--------|------------|-------------|--------------|-----------------|---------------------|------------|---------------------|------------|
| 9   | rs10811661 | CDKN2A/B   | T           | 0.60         | 0.54            | 0.07                | 1.28(1.21-1.36) | <0.00001 | [10-12]              |
| 8   | rs13266634 | SLC30A8    | C           | 0.58         | 0.52            | 0.10                | 1.19(1.13-1.25) | <0.00001 | [6,10-12,27]         |
| 6   | rs10946398 | CDKAL1     | C           | 0.45         | 0.41            | 0.03                | 1.24(1.13-1.37) | <0.00001 | [10,12,15]           |
| 11  | rs2337892  | KCNQ1      | C           | 0.72         | 0.66            | 0.01                | 1.33(1.18-1.49) | <0.00001 | [23-26]              |
| 4   | rs6446482  | WFS1       | G           | 0.96         | 0.95            | 0.53                | 1.26(1.06-1.51) | 0.009     | [12]                  |
| 10  | rs5015480  | HHEX       | C           | 0.20         | 0.16            | 0.12                | 1.24(1.12-1.38) | <0.00001 | [10,11]              |
| 17  | rs7501939  | TCF2       | T           | 0.28         | 0.26            | 0.88                | 1.16(1.08-1.24) | <0.00001 | [5,38]               |
| 3   | rs4402960  | IGF2BP2    | T           | 0.27         | 0.24            | 0.22                | 1.14(1.06-1.22) | 0.0002   | [10,11,15]           |
| 16  | rs8050136  | FTO        | A           | 0.14         | 0.12            | 0.80                | 1.17(1.09-1.27) | <0.00001 | [11,12,14,30]        |

AF: allele frequency; OR: Odds ratio; CI: confidence interval; All of the calculations for the meta-analysis were carried out on Revman4.2. Cochran’s x²-based Q-statistic test was used to assess heterogeneity in all studies, and a random-effect model was adopted when heterogeneity existed; otherwise a fixed-effects model was appropriate. Combined ORs were calculated using the Mantel-Haenszel (fixed-effects) and DerSimonian and Laird (random-effects) tests. The significant P value of the overall ORs was determined using a Z-test.

Genotype-phenotype relationship analysis

**Genotype-age of diagnosis (AOD) for diabetes**

For the patients with T2D, multiple linear regression was used to evaluate the effect of nine representative SNPs on AOD with adjustment for gender and BMI under a priori models. The analysis revealed that only WFS1-rs6446482 was negatively related to AOD under a dominant model (p = 0.02), and the patients with one or two risk alleles of WFS1-rs6446482 were diagnosed approximately 3 years earlier than those without risk alleles (49 ± 11 years versus 52 ± 11 years, p = 0.03). Prompted by this observation, we performed a subgroup analysis of 406 early-onset T2D patients (age of diagnosis ≥45 years) and 973 control subjects, showing that WFS1-rs6446482 was significantly associated with early-onset T2D (risk allele-specific OR, 1.96; 95% CI, 1.05-4.76; nominal p = 0.03; empirical p = 0.03) after adjustment for gender, age, and BMI.

**Genotype-BMI**

For analysis of the genotype-BMI relationship, only the control subjects were examined because the treatment for T2D might distort the relationship. Only FTO-rs8050136 of nine genetic loci was found to be significantly associated with BMI (p = 0.04) after adjusting for gender and age as covariates. The individuals with one or two risk alleles had a higher BMI (25. ± 3.3 kg/m², n = 205) than those without a risk allele (24.8 ± 3.4 kg/m², n = 790; p = 0.04).

**Genotype-beta cell function and insulin resistance**

Because the insulin level might be influenced by a hyperglycemic agent, 493 non-diabetic control subjects with fasting insulin concentrations available were studied. Only at the FTO and CDKAL1 loci was a relationship between SNP and phenotype observed. As shown in
Table 4, the individuals with a risk allele of FTO-rs8050136 had a higher HOMA-i, HOMA-IR, BMI, and fasting serum insulin level than those without the risk allele (under a dominant model), and the effects of FTO on HOMA-i, HOMA-IR, and the fasting serum insulin level were independent of gender, age, and BMI. In addition, CDKAL1-rs10946398 significantly affected beta cell function independent of gender, age, and BMI, and the individuals with 2 risk alleles had a lower HOMA-i than those without a risk allele (under the recessive model).

Discussion

In the present study, we have replicated the associations between seven SNPs (CDKAL1-rs10946398, IGF2BP2-rs4402960, SLC30A8-rs13266634, CDKN2A/B-rs10811661, HHEX-rs5015480, FTO-rs8050136, and KCNQ1-rs2237892) with T2D in the Chinese Han population living in China, and an association between WFS1-rs6446482 with early-onset T2D was also identified in the subgroup analysis. For the genotype-phenotype analysis in control subjects, we found that the SNP at FTO locus showed a significant association with BMI, beta cell function, and insulin sensitivity. Moreover, we observed the influence of CDKAL1 on beta cell function, and our meta-analysis also indicated the SNPs at TCF2-rs7501939 and WFS1-rs6446482 were associated with T2D.

SLC30A8, HHEX, CDKAL1, CDKN2A/B, IGF2BP2, and FTO are among the first cohort of susceptibility genes discovered in relatively small samples by GWAS with ORs ranging from 1.14-1.20 [1-6], and slightly higher than the Caucasian population [1-6], and slightly different from other Chinese studies. This is partly due to the features of our study (e.g., small sample sizes, enriched subjects with earlier onset T2D, and older subjects without a family history of T2D in the control group) or the difference in the studied population in genetic background as observed for the TCF7L2 and KCNQ1 genes in previous reports [7,21,22]. Based on our observation, we found that the minor allele frequencies of FTO, WFS1, TCF2, HHEX, and IGF2BP2 were much lower, while those of CDKAL1, CDKN2A/B, SLC30A8, and KCNQ1 were much higher than in the Caucasian population (Additional file 1, Table S1), indicating the different genetic background between Caucasians and the Chinese population. Our findings on CDKAL1, SLC30A8, CDKN2A/B, and KCNQ1 are further supported by several recent studies in the Chinese population [10-12,23-27]. However, for IGF2BP2, no significant association was demonstrated with T2D [10,11]. For HHEX, a relationship between the SNPs at the HHEX locus and T2D was reported among Chinese living in Shanghai, but not among Chinese in Beijing, even in the same study [10]. We believe that the inconsistent results of these studies are due, at least in part, to the small sample size [10] and the different enrollment criteria. For example, the plasma glucose at 2 hours during the OGTT was not determined and some subjects with impaired glucose tolerance (IGT) or T2D might have been falsely classified into the control group [10], or some adolescents in the control group may develop T2D in the future [11]. Therefore, the meta-analysis of the combined data from these published studies

Table 4: The genotype-phenotype relationship in control individuals at CDKAL1 and FTO genetic loci.

| SNPs    | Genotype | Mean ± SD | Additive p-value | Recessive p-value |
|---------|----------|-----------|------------------|-------------------|
|         | Male/     | Age (yrs) | Fasting glucose  | Fasting insulin   |
|         | Female    | BMI (kg/m²) | (mmol/l)         | (pmol/l)          |
|         |           |           |                  |                   |
| CDKAL1  | rs10946398|           |                  |                   |
| AA      | 40/117    | 57 ± 8    | 25.1 ± 2.9       | 5.2 ± 0.4         | 50.1(34.1-71.7) | 81.5(59.2-118.1) | 1.6(1.2-2.5) |
| AC      | 65/188    | 57 ± 8    | 25.1 ± 3.2       | 5.3 ± 0.4         | 46.7(36.9-66.9) | 80.5(57.3-109.8) | 1.5(1.1-2.3) |
| CC      | 22/56     | 57 ± 9    | 25.9 ± 3.6       | 5.4 ± 0.4         | 48.1(36.9-64.8) | 77.1(57.4-106.3) | 1.6(1.2-2.3) |
| Dominant p-value | -      | 0.650     | 0.140            | 0.268             | 0.142           | 0.268            |
| Additive p-value | -      | 0.131     | 0.161            | 0.525             | 0.034(0.019)a   | 0.155            |
| Recessive p-value | -     | 0.053     | 0.044(0.046)a    | 0.802             | 0.043(0.021)a   | 0.228            |
| FTO     | rs8050136 |           |                  |                   |
| CC      | 108/278   | 57 ± 8    | 25.1 ± 3.2       | 5.3 ± 0.4         | 45.3(32.7-63.4) | 76.6(54.3-106.3) | 1.5(1.1-2.2) |
| CA/AA   | 19/85     | 57 ± 8    | 25.8 ± 3.2       | 5.2 ± 0.4         | 55.7(43.2-75.2) | 94.3(73.5-129.6) | 1.81(4.2-6)   |
| Dominant p-value | -      | 0.04(0.037)b| 0.148           | <0.00001(0.005)a  | 0.004(0.017)a   | 0.005(0.035)a   |

Data are the means ± SD, or median (interquartile range). Test models refer to the minor allele. Only the dominant model was considered in which the minor allele homozygote count was ≤10. Bold: p-value < 0.05. Unadjusted p-values without parentheses and p-values with parentheses adjusted for a (gender, age, and BMI) and b (gender and age).
and our study is necessary for evaluating the association of these genetic loci with T2D and the effect of size in the Chinese population.

The studies in other ethnic groups have made clear that the association between FTO and T2D is mediated through its effect on body weight [2,3,28,29]. In the present study, we have confirmed the association between FTO and BMI and T2D, and the association with T2D remained of borderline significance (p = 0.046), even after adjustment for BMI. The independent effect of FTO on T2D is consistent with a recent study [14]. It is worth noticing that the study results on FTO in a Chinese population have been conflicting. The study in Chinese living in Taiwan has reported this association with BMI, but not the association is really independent of BMI. As observed in one study, the association between FTO and T2D remained of borderline significance (p = 0.046), even after adjustment for BMI. The independent effect of FTO on T2D is consistent with a recent study [14]. It is worth noticing that the study results on FTO in a Chinese population have been conflicting. The study in Chinese living in Taiwan has reported this association with BMI, but not the association was replicated. A meta-analysis of combined data from both the previous study [38] and our study in Chinese confirmed the findings.

There are now as many as 17 genetic loci associated with T2D. In our previous Chinese Han studies [22,39,40], we have assessed the effects of PPARG, KCNJ11, and TCFL7L2, and successfully replicated the associations between the KCNJ11 and TCFL7L2 loci with T2D. However, the remaining six genetic loci were identified by meta-analysis of GWAS, including JAZF1, TSPAN8-LGR5, THADA, ADAMT59, NOTCH2-ADAM30, and MTNR1B, of which only MTNR1B in one study was shown to increase the risk for T2D and an increased fasting plasma glucose concentration in the Chinese Han [12,41]. Therefore, further investigation with a large sample and meta-analysis is needed to confirm the roles in the Chinese Han population.

Conclusions

In summary, the present study has confirmed an association between genetic variations at CDKAL1, IGF2BP2, SLC30A8, CDKNA2A/B, HHEX, KCNQ1, and FTO loci with T2D in the Chinese Han population living in China. Our meta-analysis has provided the evidence that the C allele of rs7501939 and the A allele of rs4430796 in the TCF2 gene were shown by GWAS to confer risk for prostate cancer and are protective for T2D [5]. However, that study did not show a significant association between TCF2-rs7501939 with T2D in a Chinese sample [5], consistent with the results of our study. The negative finding should be attributed to the insufficient power of this study (Additional file 1, Table S1). Nevertheless, in another Chinese study involving TCF2-rs4430796 [38], the association was replicated. A meta-analysis of combined data from both the previous study [38] and our study in Chinese confirmed the findings.

Additional material

Additional file 1 Table S1 and Table S2.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

XYH carried out this study and drafted the manuscript. LNJ contributed to the design of the study and the revision of this manuscript. YYL, QR, XYZ, FW, XQS, and XHZ offered experimental, analytic, and data assistance. All authors have read and approved this final manuscript.

Acknowledgements

We would like express our appreciation to all patients and control subjects who were involved in this study. We would also like to give our thanks to the Chinese National Human Genome Center (Shanghai) for genotyping services. This study was supported by the National Natural Science Foundation of China (30570873, 30771031), National Basic Research Program of China (973 program, 2006CB503900), 985 Program of Peking University (PUDC2007-2),
Variants in KCNQ1 are associated with type 2 diabetes and beta cell function in a Chinese population. J Clin Endocrinol Metab 2009, 94:1322-1325.

15. Han XY, Wu Y, Zhang R, Chen Z, Zhou DZ, Zhao T, Li S, Wang T, Hu F, Feng GY, Zhang ZF, He L, Xu H: Positive association between variations in CDKAL1 and type 2 diabetes in Han Chinese individuals. Diabetologia 2008, 51:2134-2137.

16. Alberti KG, Zimmet PP: Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabetes Med 1998, 15:539-553.

17. Han XY, Ji LN: Contribution of MODY2 gene to the pathogenesis of Chinese early onset familial type 2 diabetes. Beijing Da Xue Xue Bao 2005, 10:591-594.

18. Han XY, Liu YT, Ji LN: Contribution of MODY6 gene in the pathogenesis of familial type 2 diabetes in Chinese population. Zhonghua Yi Xue Za Zhi 2005, 14:2463-2467.

19. Matthews RD, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:112-129.

20. Guo D, Reynolds K, Duan X, Yin X, Chen J, Wu X, Mo J, Whelton PH, He J, InterASIA Collaborative Group: Prevalence of diabetes and impaired fasting glucose in the Chinese adult population: International Collaborative Study of Cardiovascular Disease in Asia (InterASIA). Diabetologia 2003, 46:1109-1118.

21. Ng MC, Tan CH, Lam VK, So WY, Ma RC, Chan JC: Replication and identification of novel variants at TCF7L2 associated with type 2 diabetes in Hong Kong Chinese. J Clin Endocrinol Metab 2009, 94:1322-1325.

22. Ren Q, Han XY, Wang F, Zhang XY, Han LC, Luo Y, Zhou XH, Ji LN: Exon sequencing and association analysis of polymorphisms in TCF7L2 with type 2 diabetes in a Chinese population. Diabetologia 2008, 51:1156-1163.

23. Hu F, Wang C, Zhang R, Ma X, Wang J, Lu J, Qin W, Bao Y, Xiang K, Ji W: Variations in KCNQ1 are associated with type 2 diabetes and beta cell function in a Chinese population. Diabetologia 2009, 52:1322-1325.

24. Liu Y, Zhou ZD, Chen Z, Zhao T, Zhang N, Ming M, Hu X, Yang YF, Zhang ZF, Yu L, He L, Xu H: Variants in KCNQ1 are associated with type 2 diabetes and impaired fasting glucose in the main population of mainland China. Diabetologia 2009, 52:1315-1321.

25. Qi Q, Li H, Loos RJ, Liu C, Wu Y, Hu FB, Wu H, Li L, Yu Z, Lin X: Common variants in KCNQ1 are associated with type 2 diabetes and impaired fasting glucose in a Chinese Han population. Hum Mol Genet 2009, 18:3308-3315.

26. Chen Z, Zhang X, Ma G, Qian Q, Yao Y: Association study of four variants in KCNQ1 with type 2 diabetes mellitus and premature coronary artery disease in a Chinese population. Mol Biol Rep 2010, 37:207-212.
27. Xiang J, Li XY, Xu M, Hong J, Huang Y, Tan JR, Lu X, Dai M, Yu B, Ning G: Zinc transporter-8 gene (SLC30A8) is associated with type 2 diabetes in Han Chinese individuals. J Clin Endocrinol Metab 2009, 94:4107-4112.

28. Frayling TM, Timpson NJ, Weedon MN, Zeggini E, Freathy RM, Lindgren CM, Perry JR, Elliott KS, Lango H, Rayner EW, Shields B, Harries LW, Barrett JC, Ellard S, Groves CJ, Knight B, Patch AM, Ness AR, Ebrahim S, Lavori DA, Ring SM, Ben-Shlomo Y, Jarvelin MR, Sovio U, Bennett AJ, Melzer D, Ferrucci L, Loos RJ, Barroso I, Wareham NJ, et al: A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science 2007, 316:889-894.

29. Scuteri A, Sanna S, Chen WM, Uda M, Albai G, Strait J, Najjar S, Nagaraja R, Orr M, Usala G, Mei L, Lai S, Maschio A, Busonero F, Mulas A, Ehet GB, Fink AA, Weder AB, Cooper RS, Galan P, Chakravarti A, Schlessinger D, Cao A, Lakatta E, Abecasis GR: Genome-wide association scan shows genetic variants in the FTO gene are associated with obesity-related traits. PLoS Genet 2007, 3:1200-1210.

30. Chang YC, Liu PH, Lee WJ, Chang TJ, Jiang YD, Li HY, Kuo SS, Lee KC, Chuang LM: Common variation in the fat mass and obesity-associated (FTO) gene confers risk of obesity and modulates BMI in the Chinese population. Diabetes 2008, 57:2245-2252.

31. Yoon KH, Lee JH, Kim JW, Choi YH, Ko SH, Zimmet P, Son HY: Epidemic obesity and type 2 diabetes in Asia. Lancet 2006, 368:1681-1688.

32. Torrens JI, Skurnick J, Davidow AL, Korenman SG, Santoro N, Soto-Greene JC, Ellard S, Groves CJ, Knight B, Patch AM, Ness AR, Ebrahim S, Lavori DA, Ring SM, Ben-Shlomo Y, Jarvelin MR, Sovio U, Bennett AJ, Melzer D, Ferrucci L, Loos RJ, Barroso I, Wareham NJ, et al: A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science 2007, 316:889-894.

33. Yoon KH, Lee JH, Kim JW, Cho JH, Choi YH, Ko SH, Zimmet P, Son HY: Epidemic obesity and type 2 diabetes in Asia. Lancet 2006, 368:1681-1688.

34. Ishihara H, Takeda S, Yamaguchi S, Takei D, Yamada T, Inoue H, Soga H, Katagiri H, Tanizawa Y, Oka Y: Disruption of the WFS1 gene in mice causes progressive beta-cell loss and impaired stimulus-secretion coupling in insulin secretion. Hum Mol Genet 2004, 13:1159-1170.

35. Lehman DM, Richardson DK, Jenkinson CP, Hunt KJ, Dyer TD, Leach RJ, Arya R, Abboud HE, Blangero J, Duggirala R, Stern MP: P2 promoter variants of the hepatocyte nuclear factor 4alpha gene are associated with type 2 diabetes in Mexican Americans. Diabetes 2007, 56:513-517.

36. Wang F, Han X, Chen Y, Zhang R, Bao Y, Ma X, Lu J, Qin W, Shao X, Lu J, Xu J, Lu H, Xiang K, Jia W: Common variants of hepatocyte nuclear factor 4alpha beta are associated with type 2 diabetes in a Chinese population. Diabetes 2009, 58:1023-1027.

37. Wang F, Han X, Ren Q, Zhang X, Zhuo Y, Zhou X: Effect of genetic variants in KCNJ11, ABCB8, PPARG and HNF4A loci on the susceptibility of type 2 diabetes in Chinese Han population. Chin Med J (Engl) 2009, 122:2477-2482.

38. Luo Y, Wang H, Han X, Ren Q, Wang F, Zhang X, Sun X, Zhou X, Ji L: Meta-analysis of the association between SNPs in TCF7L2 and type 2 diabetes in East Asian population. Diabetes Res Clin Pract 2009, 85:139-146.

39. Rönn T, Wen J, Yang Z, Lu B, Du Y, Groop L, Hu R, Ling C: A common variant in MTNR1B, encoding melatonin receptor 1B, is associated with type 2 diabetes and fasting plasma glucose in Han Chinese individuals. Diabetologia 2009, 52:830-833.

Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2350/11/81/prepub